{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-24-000013","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.926434+00:00","generated_at":"2026-06-04T02:50:00.827965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbbVie updates 2024 EPS guidance after incurring $164M IPR&D expense in Q1","bullets":["Acquired IPR&D and milestones expense of $164M pre-tax ($0.08 per share) recorded in Q1 2024.","Q1 2024 adjusted diluted EPS guidance revised to $2.18-$2.22 from $2.26-$2.30 previously.","Full-year 2024 adjusted diluted EPS guidance revised to $10.97-$11.17 from $11.05-$11.25.","Future IPR&D and milestones expense excluded from guidance due to unpredictable deal timing."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-24-000013","json":"https://secwatch.observer/filing/0001551152-24-000013.json","markdown":"https://secwatch.observer/filing/0001551152-24-000013.md","text":"https://secwatch.observer/filing/0001551152-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000013/0001551152-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000013/abbv-20240403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:50:00.827965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}